OS Therapies Incorporated (OSTX)
| Market Cap | 73.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.55M |
| Shares Out | 20.88M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,754 |
| Open | 3.530 |
| Previous Close | 3.530 |
| Day's Range | 3.450 - 3.765 |
| 52-Week Range | 2.510 - 4.900 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 21.00 (+496.59%) |
| Earnings Date | Aug 15, 2024 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Mary... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for OSTX stock is "Strong Buy" and the 12-month stock price forecast is $21.0.
News
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today annou...
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian ca...
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its par...
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today anno...
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it...
OS Therapies Clarifies CUSIP of Common Stock
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarif...
OS Therapies Reports Second Quarter 2024 Financial Results
Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financials Conversion of all repor...
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stoc...
OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board
ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopha...
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing
OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board
ROCKVILLE, Md. & NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical compa...
OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”
ROCKVILLE, Md. & NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (“OS Therapies” or the “Company”) (NYSE-A: OSTX), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical stage b...
OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic can...
OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic can...
OS Therapies IPO Registration Document (S-1)
OS Therapies has filed to go public with an IPO on the NYSE American.